Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
The parade of earnings continues next week, Jim Cramer told his Mad Money viewers Friday as he laid out his game plan for next week's trading.
On Monday, Cramer said, Cardinal Health (CAH - Get Report) will have his attention after falling 9.7% today. He said Cardinal must address its price-war issues head on. Also on Monday, Zimmer Biomet (ZBH - Get Report) , a stock that's usually good to buy on weakness, but might be under pressure this quarter.
Next on Tuesday, it's Royal Dutch Shell (RDSA) and Occidental Petroleum (OXY - Get Report) , another Action Alerts PLUS holding, reporting, along with Pioneer Natural Resources (PXD - Get Report) and Gilead Sciences (GILD - Get Report) . Cramer was a buyer of Pioneer, but said Gilead will be under pressure with the rest of the health-care sector.
Wednesday brings earnings from Amerisource Bergen (ABC - Get Report) and Cramer says he's not a fan. He's also bearish on Clorox (CLX - Get Report) and Whole Foods Market (WFM) , but did find some love for Facebook (FB - Get Report) , which is also a part of his charitable trust.
Finally on Friday, investors will learn the latest non-farm payroll numbers and Cramer said if they're strong, an interest rate hike in December will be more likely.
Drug Wholesalers Battle It Out
For a long time, the drug wholesalers had a nice equilibrium, Cramer told viewers, a happy oligopoly with little or no real competition. But that all changed this quarter as Amerisource Bergen took aim at rivals McKesson (MCK - Get Report) and Cardinal Health, starting a vicious price war that sent shares of McKesson plummeting 22.6% and Cardinal down nearly 10%.
Amerisource has made it clear that it wants to increase market share, offering steep enough discounts on certain generic drugs to give independent drug stores the incentive to break their usual three-year agreements and jump to Amerisource.
While the price war may ultimately be great news for the likes of Walgreens Boots Alliance (WBA - Get Report) and other drugstore chains, for the three wholesalers -- which control 97% of the market -- Cramer said the damage could be extensive.
"Everyone gets hurt," Cramer concluded, and since it's hard to know where the pain will end, this group must be off-limits until further notice.
Shares of Avon hit $24 in 2013. Then they went into a downward spiral, cratering to as low as $2.50 in 2015. That was due to falling sales and bad management, Cramer said, which pressured gross margins and crippled earnings.
But then came a deal with Cerberus Capital, which provided a $170 million cash infusion and allowed Avon to focus on its high-growth international markets.
Since the Cerberus deal was announced, shares of Avon have slowly risen 165%, as the company had a plan and the means to execute on it. When it last reported, the company delivered a five-cents-a-share earnings beat, with better-than-expected sales and was able to clean up its balance sheet to boot. Additionally, Avon saw positive growth in nine of its top 10 markets -- news which caused analysts to start taking notice.
Cramer said while he feels the turnaround at Avon is indeed for real, the market has been brutal this earnings season, which made him caution to not buy Avon ahead of earnings and wait for weakness.
Off The Tape: SimpliVity
In his "Off The Tape" segment, Cramer sat down with Doron Kempel, CEO of the privately held SimpliVity, the IT infrastructure company specializing in hyper-convergence.
Kempel explained that just as the iPhone replaced with a single device multiple personal electronic devices such as the phone, camera, laptop, compass and music player, SimpliVity aims to replace servers, storage, and routers and similar equipment for enterprise with a single device.
SimpliVity was able to replace 34 refrigerator-size racks of equipment for a client and replace them with just three racks, saving money, power and labor in a 11:1 reduction in overall equipment.
Cramer said while SimpliVity is not publicly traded, this is the disruptive technology that investors need to keep an eye out for.
In the Lightning Round, Cramer was bullish on Smith & Wesson (SWHC) , The Blackstone Group (BX - Get Report) , Anika Therapeutics (ANIK - Get Report) , Boston Scientific (BSX - Get Report) and Juniper Networks (JNPR - Get Report) .
No Huddle Offense
Too often Wall Street views big spending plans and bold initiatives negatively, Cramer explained, and that's why shares of Amazon immediately sank 5% yesterday, after Bezos explained he was spending more to win markets Amazon has not yet conquered.
But while Wall Street may like slow-growing, predictable earnings, Cramer said, over the long run, investors have been and will continue to be rewarded by sticking with one of the great entrepreneurs of our time. Yesterday's weakness, he concluded, is just another buying opportunity.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.